8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
Key Takeaways
- First-line maintenance therapy in advanced high-grade serous ovarian cancer is dictated by homologous recombination repair deficiency (HRD) and BRCA status: germline/somatic BRCA-mutated tumors derive profound, long-term overall survival benefit from olaparib maintenance for 2 years (SOLO-1), HRD-positive tumors benefit from olaparib + bevacizumab (PAOLA-1) or niraparib (PRIMA), whereas HRD-negative/proficient tumors derive minimal benefit from PARP monotherapy.
- Mirvetuximab soravtansine (anti-FRalpha ADC with DM4 maytansinoid payload) is standard-of-care for FRalpha-positive (>=75% of cells with >=2+ intensity) platinum-resistant ovarian cancer (MIRASOL trial); pharmacists must enforce protocolized ophthalmic care (topical steroid drops, lubricating artificial tears) to prevent severe corneal keratopathy.
- Endometrial cancer classification incorporates TCGA molecular stratification: POLE ultramutated (favorable prognosis), dMMR/MSI-High (highly checkpoint inhibitor-responsive), p53 abnormal (aggressive serous-like, poor prognosis), and NSMP; frontline therapy for advanced dMMR endometrial cancer integrates dostarlimab or pembrolizumab with carboplatin + paclitaxel (RUBY / NRG-GY018).
- Second-line therapy for recurrent mismatch repair proficient (pMMR) endometrial cancer combines lenvatinib 20 mg PO daily with pembrolizumab 200 mg IV Q3W (KEYNOTE-775), requiring proactive management of severe VEGFR-mediated hypertension, proteinuria, and fistula risks.
- Locally advanced cervical cancer is cured with definitive concurrent chemoradiation (CCRT: external beam radiation + brachytherapy + weekly radiosensitizing cisplatin 40 mg/m2), while persistent/metastatic cervical cancer requires platinum + paclitaxel + bevacizumab + pembrolizumab for PD-L1 CPS >= 1 (KEYNOTE-826); tisotumab vedotin provides an active second-line ADC option requiring strict ocular mitigation.
8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
Gynecologic malignancies encompass distinct anatomical and molecular entities: Epithelial Ovarian Cancer (EOC), Endometrial Carcinoma, and Cervical Cancer. Recent advancements in precision oncology have transformed gynecologic cancer care through the integration of Homologous Recombination Deficiency (HRD) testing, The Cancer Genome Atlas (TCGA) molecular classification, Mismatch Repair (MMR) profiling, and novel Antibody-Drug Conjugates (ADCs).
Board-certified oncology pharmacists must command the molecular diagnostics, pharmacotherapy regimens, toxicities, and supportive care protocols governing these malignancies.
1. Epithelial Ovarian Cancer: Primary Therapy & Maintenance Algorithms
High-Grade Serous Ovarian Cancer (HGSOC) represents ~70–80% of ovarian malignancies and is characterized by ubiquitous TP53 mutations and high rates of Homologous Recombination Repair Deficiency (HRD) (~50% of tumors harbor germline/somatic BRCA1/2 mutations or non-BRCA HRD genomic scarring).
Primary Cytoreduction & Frontline Systemic Chemotherapy
- Primary Debulking Surgery: The cornerstone of initial management. Surgical goal is complete cytoreduction (R0: no gross macroscopic residual disease) or optimal debulking (<1 cm residual).
- Frontline Platinum-Taxane Doublet:
- Carboplatin (AUC 5–6 IV) + Paclitaxel (175 mg/m2 IV over 3 hours) every 21 days for 6 cycles.
- Dose-Dense Paclitaxel (JGOG 3016 / GOG-262): Paclitaxel 80 mg/m2 IV weekly on Days 1, 8, 15 + Carboplatin AUC 6 Q3W.
- Bevacizumab Incorporation (GOG-218 / ICON7): Bevacizumab (15 mg/kg IV Q3W) added to cycles 2–6 and continued as maintenance for 15–22 total cycles in patients with Stage III suboptimally debulked (>1 cm residual) or Stage IV disease.
+-----------------------------------------------------------------------------+
| FRONTLINE OVARIAN CANCER MAINTENANCE ALGORITHM |
| |
| RESPONSE (CR or PR) TO FRONTLINE PLATINUM-BASED CHEMOTHERAPY |
| (Determine: Germline/Somatic BRCA1/2 Mutation and HRD Genomic Status) |
| | |
| +-------------------------+-------------------------+ |
| | | |
| v v |
| [gBRCA or sBRCA MUTATED] [BRCA WILD-TYPE] |
| (SOLO-1 Trial: Moore NEJM 2018) | |
| - **OLAPARIB MONOTHERAPY** | |
| 300 mg PO BID for 2 YEARS | |
| - 7-year OS: **67.0% vs. 46.5%** | |
| (OS HR 0.55, p = 0.0004) | |
| - OR Olaparib + Bevacizumab (PAOLA-1) | |
| - OR Niraparib Monotherapy (PRIMA) | |
| | |
| +-----------------------------------------+ |
| | | |
| v v |
| [HRD-POSITIVE / BRCA WT] [HRD-NEGATIVE / HRP] |
| (PAOLA-1 & PRIMA Trials) (Homologous Recomb Prof) |
| - Option 1: **OLAPARIB + BEVACIZUMAB** (PAOLA-1) - Option 1: **BEVACIZUMAB|
| * Olaparib 300 mg BID x 2 yrs + Bevacizumab MONOTHERAPY** (GOG-218)|
| 15 mg/kg Q3W x 15 mos (mPFS 37.2 vs 17.7m; 15 mg/kg Q3W to finish |
| HR 0.33, p < 0.0001) 15-22 cycles |
| - Option 2: **NIRAPARIB MONOTHERAPY** (PRIMA) - Option 2: **NIRAPARIB**|
| * Individualized 200/300 mg daily x 3 years (Modest PFS HR 0.68) |
| - Option 3: OBSERVATION |
| - *(Olaparib is NOT rec)*|
+-----------------------------------------------------------------------------+
Platinum-Sensitive vs. Platinum-Resistant Recurrent Disease
- Platinum-Sensitive Recurrence (Platinum-Free Interval [PFI] >= 6 months): Rechallenge with platinum-based doublet: Carboplatin + Pegylated Liposomal Doxorubicin (PLD) (preferred over paclitaxel per CALYPSO due to lower neuropathy/alopecia), Carboplatin + Gemcitabine +/- Bevacizumab (OCEANS), or Carboplatin + Paclitaxel +/- Bevacizumab (GOG-213). Followed by PARP inhibitor maintenance if PARP-naive.
- Platinum-Resistant Recurrence (PFI < 6 months): Poor prognosis; single-agent non-platinum cytotoxic therapy (PLD, weekly paclitaxel, topotecan, gemcitabine) +/- Bevacizumab (AURELIA trial: adds bevacizumab 10 mg/kg Q2W or 15 mg/kg Q3W, doubling ORR and PFS).
+-----------------------------------------------------------------------------+
| MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT EOC |
| |
| [TARGET & MOLECULAR STRUCTURE] (MIRASOL Trial: Moore et al. NEJM 2023) |
| - Anti-Folate Receptor Alpha (**FRalpha**) Monoclonal Antibody ADC |
| - Payload: **DM4** (Potent maytansinoid microtubule-disrupting agent) |
| - Indication: FRalpha-positive (>=75% tumor cells with >=2+ intensity by |
| Ventana FOLR1 Assay) platinum-resistant ovarian cancer (1-3 prior lines)|
| - Dosing: **6 mg/kg Adjusted Ideal Body Weight (AIBW) IV Q3W** |
| - Efficacy: Superior PFS (HR 0.65) and OS (**16.5 vs. 12.8 months**, |
| HR 0.67, p = 0.0046) over physician's choice chemotherapy! |
+-----------------------------------------------------------------------------+
+-----------------------------------------------------------------------------+
| MANDATORY MIRVETUXIMAB OPHTHALMIC CARE PROTOCOL |
| |
| - Pathophysiology: DM4 payload uptake into corneal epithelial cells |
| causes microcystic corneal deposits, keratopathy, and visual blurring. |
| |
| [PRE-TREATMENT & ONGOING SURVEILLANCE] |
| - Baseline comprehensive ophthalmic exam (visual acuity + slit lamp). |
| - Repeat ophthalmic exam every cycle for first 8 cycles, then Q2 cycles. |
| |
| [MANDATORY TOPICAL PROPHYLAXIS] |
| 1. Topical Corticosteroid Eye Drops: Prednisolone acetate 1% (or equivalent|
| dexamethasone) **1 drop in each eye TID on Days 1 to 8** of each cycle. |
| 2. Lubricating Eye Drops (Artificial Tears): Preservative-free drops |
| instilled **at least 4 to 6 times daily** while awake throughout Tx. |
| 3. Contact Lens Prohibition: Avoid contact lenses during entire treatment |
| until at least 30 days after treatment discontinuation. |
+-----------------------------------------------------------------------------+
2. Endometrial Carcinoma: TCGA Molecular Classification & Therapeutics
Endometrial carcinoma is the most common gynecologic malignancy in developed countries. The traditional Bokhman classification (Type I endometrioid vs. Type II serous/clear cell) has been superseded by The Cancer Genome Atlas (TCGA) / Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular stratification:
+-----------------------------------------------------------------------------+
| TCGA / ProMisE MOLECULAR CLASSIFICATION |
| |
| 1. POLE ULTRAMUTATED (~10%): |
| - Exonuclease domain mutations in DNA polymerase epsilon (*POLE*) |
| - Ultra-high tumor mutational burden (>100 mut/Mb); marked immune infil|
| - **PROGNOSIS: EXCELLENT.** Virtually 0% recurrence; candidates for |
| de-escalation (omission of adjuvant chemo/radiation). |
| |
| 2. MISMATCH REPAIR DEFICIENT / MSI-HIGH (dMMR / MSI-H; ~25-30%): |
| - Loss of MLH1, MSH2, MSH6, or PMS2 (Lynch Syndrome or MLH1 promoter |
| hypermethylation). High microsatellite instability and high TMB. |
| - **PROGNOSIS: INTERMEDIATE.** Outstanding responsiveness to Immune |
| Checkpoint Inhibitors (Dostarlimab, Pembrolizumab). |
| |
| 3. p53 ABNORMAL / SEROUS-LIKE / COPY NUMBER-HIGH (p53abn; ~15%): |
| - *TP53* missense/null mutation; diffuse p53 IHC overexpression/null. |
| - High genomic instability, aneuploidy; ~30% HER2 amplification. |
| - **PROGNOSIS: POOR / AGGRESSIVE.** High recurrence; requires intensive|
| chemotherapy (Carboplatin+Paclitaxel +/- Trastuzumab if HER2+). |
| |
| 4. NO SPECIFIC MOLECULAR PROFILE / COPY NUMBER-LOW (NSMP; ~45-50%): |
| - *POLE* WT, MMR-intact (pMMR), p53-wild-type. Highly ER/PR positive. |
| - **PROGNOSIS: INTERMEDIATE.** Responsive to hormonal therapies. |
+-----------------------------------------------------------------------------+
Advanced & Metastatic Endometrial Cancer Pharmacotherapy
+-----------------------------------------------------------------------------+
| ADVANCED / RECURRENT ENDOMETRIAL CANCER TREATMENT MATRIX |
| |
| [FRONTLINE dMMR / MSI-HIGH POPULATION] |
| - **RUBY Trial (Mirza et al. NEJM 2023):** |
| * Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) + **DOSTARLIMAB** (500mg)|
| Q3W x 6 cycles -> Dostarlimab Maintenance (1000 mg Q6W for 3 years) |
| * 24-month PFS: **61.4% vs. 15.7%** (HR 0.28, p < 0.0001) |
| - **NRG-GY018 / KEYNOTE-868 (Eskander et al. NEJM 2023):** |
| * Carboplatin + Paclitaxel + **PEMBROLIZUMAB** (200 mg Q3W -> 400 mg Q6W)|
| * PFS HR: **0.30** (p < 0.0001) in dMMR cohort |
| |
| [SECOND-LINE pMMR / MSS POPULATION (KEYNOTE-775 / Study 309)] |
| - **LENVATINIB** (20 mg PO daily) + **PEMBROLIZUMAB** (200 mg IV Q3W) |
| - Significantly superior to doxorubicin/paclitaxel: Median OS **17.4 vs. |
| 12.0 months** (HR 0.68, p < 0.0001); Median PFS **6.6 vs. 3.8 months** |
| - Toxicity Management: Proactive blood pressure control (Grade 3 HTN 42%),|
| proteinuria, diarrhea, weight loss, dysphonia, fistula surveillance. |
| |
| [SECOND-LINE dMMR / MSI-HIGH MONOTHERAPY] |
| - **Dostarlimab** 500 mg Q3W x 4, then 1000 mg Q6W (GARNET Trial) OR |
| - **Pembrolizumab** 200 mg Q3W or 400 mg Q6W (KEYNOTE-158 Trial) |
| |
| [ADVANCED HER2-OVEREXPRESSING p53abn SEROUS CARCINOMA] |
| - Carboplatin + Paclitaxel + **Trastuzumab** (Fader et al. JCO 2018/2020) |
| - Prolongs median PFS (12.6 vs 8.0 mo, HR 0.44) and OS (29.6 vs 24.4 mo) |
+-----------------------------------------------------------------------------+
3. Cervical Carcinoma: Prevention, Chemoradiation & Metastatic Strategies
Virtually all cervical carcinomas (>95%) are etiologically linked to persistent infection with high-risk Human Papillomavirus (HPV) subtypes, predominantly HPV-16 (~50–60%) and HPV-18 (~15–20%). Viral oncoproteins E6 (which binds and accelerates ubiquitin-mediated degradation of p53) and E7 (which binds and inactivates retinoblastoma protein pRb) drive genomic instability and uninhibited G1/S cell cycle progression.
Prevention & Primary Screening
- Primary Prevention: Recombinant 9-valent HPV vaccine (Gardasil-9, covering HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58). Recommended at age 11–12 years (2-dose series if started before age 15; 3-dose series at 0, 1–2, 6 months if started at age >=15 or in immunocompromised individuals). FDA approved up to age 45.
- Secondary Prevention: High-risk HPV DNA co-testing and cervical cytology (Pap smear).
Locally Advanced Cervical Cancer (FIGO Stage IB3–IVA)
The standard of care is definitive Concurrent Chemoradiation (CCRT) combining External Beam Radiation Therapy (EBRT) and Image-Guided Brachytherapy with radiosensitizing weekly Cisplatin:
- Cisplatin Dosing: 40 mg/m2 IV weekly (maximum single dose: 70 mg) administered 1–2 hours prior to radiation on Days 1, 8, 15, 22, 29 (for 5–6 weekly doses during EBRT).
- Mechanism of Radiosensitization: Cisplatin inhibits the sublethal repair of radiation-induced DNA double-strand breaks, synchronizes malignant cells into the radiosensitive G2/M phase, and overcomes hypoxic radioresistance.
- KEYNOTE-A18 Integration: In high-risk locally advanced cervical cancer (FIGO 2014 Stage III–IVA, or Stage IB2–IIB node-positive), adding Pembrolizumab (200 mg Q3W x 5 cycles concurrent with CCRT, followed by 400 mg Q6W for up to 15 maintenance cycles) significantly prolonged PFS and OS.
Metastatic / Recurrent Cervical Cancer Therapeutics
+-----------------------------------------------------------------------------+
| METASTATIC / RECURRENT CERVICAL CANCER ALGORITHMS |
| |
| [FRONTLINE STANDARD (PD-L1 CPS >= 1)] (KEYNOTE-826: Monk NEJM 2021) |
| - **PEMBROLIZUMAB + PLATINUM + PACLITAXEL +/- BEVACIZUMAB** |
| * Pembrolizumab: 200 mg IV Q3W |
| * Cisplatin: 50 mg/m2 IV Q3W (OR Carboplatin AUC 5 IV Q3W) |
| * Paclitaxel: 175 mg/m2 IV Q3W |
| * Bevacizumab: 15 mg/kg IV Q3W (Omit if high fistula/perforation risk) |
| - Landmark Efficacy: Median OS **28.6 vs. 16.5 months** (HR 0.64, p<0.001)|
| |
| [SECOND-LINE ADC: TISOTUMAB VEDOTIN] (innovaTV 301: de Bono NEJM 2024) |
| - Target: **Tissue Factor (TF)** overexpressed in cervical cancer |
| - Payload: **Monomethyl auristatin E (MMAE)** (Microtubule inhibitor) |
| - Dose: **2.0 mg/kg IV Q3W** (Max 200 mg) |
| - Significant OS prolongation (HR 0.70, p = 0.0038) over chemotherapy |
+-----------------------------------------------------------------------------+
+-----------------------------------------------------------------------------+
| MANDATORY TISOTUMAB VEDOTIN EYE CARE PROTOCOL |
| |
| - Pathophysiology: TF expression in conjunctiva + MMAE uptake induces |
| conjunctivitis, blepharitis, keratitis, and corneal ulceration (50-60%).|
| |
| [PROTOCOLIZED 4-STEP OCULAR MITIGATION BUNDLE] |
| 1. Ophthalmic Vasoconstrictor: Instill **Brimonidine tartrate 0.2%** (or |
| phenylephrine) eye drops in each eye immediately prior to infusion. |
| 2. External Cold Therapy: Apply **cooling eye pads / gel packs** bilaterally|
| over closed eyes during the entire 30-minute IV infusion. |
| 3. Topical Steroid Eye Drops: Instill **Dexamethasone 0.1%** (or equiv) |
| eye drops 1 drop TID in each eye on **Days 1, 2, and 3** of each cycle. |
| 4. Lubricating Drops: Preservative-free artificial tears >= 4 times daily.|
| - Strictly prohibit contact lenses for duration of treatment. |
+-----------------------------------------------------------------------------+
4. Gynecologic Oncology Master Pharmacotherapy Matrix
| Cancer Type | Setting / Subtype | Preferred Regimen & Dosing | Landmark Trial Citation | Clinical Pharmacist Interventions & Monitoring |
|---|---|---|---|---|
| Ovarian | Frontline Maintenance (g/sBRCAm) | Olaparib: 300 mg PO BID for 2 years | SOLO-1 (Moore et al. NEJM 2018) | Monthly CBC for anemia/neutropenia; monitor SCr (OCT2/MATE1 inhibition). Dose reduce to 200 mg BID for CrCl 31–50 mL/min. |
| Ovarian | Frontline Maintenance (HRD-Positive) | Olaparib: 300 mg PO BID x 2 yrs + Bevacizumab: 15 mg/kg Q3W x 15 mos | PAOLA-1 (Ray-Coquard et al. NEJM 2019) | Dual mechanism: PARP trapping + anti-angiogenesis. Monitor BP, urine protein/creatinine ratio, cytopenias. |
| Ovarian | Platinum-Resistant (FRalpha-High) | Mirvetuximab Soravtansine: 6 mg/kg AIBW IV Q3W | MIRASOL (Moore et al. NEJM 2023) | Mandatory eye care: Prednisolone 1% eye drops TID on D1–8; lubricating artificial tears QID; periodic slit-lamp exams. Peripheral neuropathy surveillance. |
| Endometrial | Advanced / Primary Recurrent (dMMR / MSI-H) | Dostarlimab: 500 mg Q3W x 6 cycles (+ Carbo/Pac) -> 1000 mg Q6W x 3 yrs | RUBY (Mirza et al. NEJM 2023) | Immune checkpoint inhibitor irAE monitoring (thyroid, colitis, pneumonitis, hepatitis). Outstanding durability in dMMR. |
| Endometrial | Advanced Recurrent (pMMR / MSS) | Lenvatinib: 20 mg PO daily + Pembrolizumab: 200 mg IV Q3W | KEYNOTE-775 (Makker et al. NEJM 2022) | Severe hypertension: Initiate amlodipine/ACEi proactively. Monitor proteinuria, TSH (hypothyroidism in >50%), fistula/perforation. |
| Cervical | Locally Advanced (Stage IB3–IVA) | Cisplatin: 40 mg/m2 IV weekly (max 70 mg) x 5–6 doses + Radiotherapy | Standard CCRT / KEYNOTE-A18 | Cisplatin is a radiosensitizer. Ensure aggressive pre/post hydration (1 L NS) and weekly monitoring of serum creatinine, potassium, and magnesium. |
| Cervical | Metastatic Frontline (PD-L1 CPS >= 1) | Pembrolizumab: 200 mg Q3W + Carbo (AUC 5) / Cisplatin (50 mg/m2) + Paclitaxel (175 mg/m2) + Bevacizumab (15 mg/kg) | KEYNOTE-826 (Monk et al. NEJM 2021) | Screen for vesicovaginal / rectovaginal fistula risk before administering bevacizumab. Prophylactic G-CSF for 4-drug myelosuppression. |
A 59-year-old woman with newly diagnosed FIGO Stage IIIC high-grade serous epithelial ovarian cancer undergoes primary optimal cytoreductive surgery followed by 6 cycles of carboplatin (AUC 6) and paclitaxel (175 mg/m2), achieving a clinical and radiographic complete response (normal CA-125 and no evidence of disease on CT). Molecular tumor analysis reveals a somatic BRCA2 pathogenic mutation (sBRCA2+) and an HRD-positive genomic score of 68. According to the landmark SOLO-1 and PAOLA-1 trials, what is the most appropriate, evidence-based frontline maintenance strategy?
A 63-year-old woman with recurrent, platinum-resistant high-grade serous ovarian cancer (progressed 3 months after second-line carboplatin-liposomal doxorubicin) is found to have high Folate Receptor Alpha (FRalpha) tumor expression (85% of tumor cells with 3+ staining by immunohistochemistry). She is prescribed mirvetuximab soravtansine at the standard dose of 6 mg/kg (adjusted ideal body weight) IV every 3 weeks per the MIRASOL trial. Which of the following represents the required ophthalmic supportive care bundle that the clinical oncology pharmacist must establish before and during therapy?
A 66-year-old woman with recurrent endometrioid endometrial carcinoma experiences symptomatic pelvic and retroperitoneal progression 6 months after completing adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy. Immunohistochemistry and molecular testing confirm that the tumor is mismatch repair proficient (pMMR) / microsatellite stable (MSS) and p53 wild-type. According to the Phase 3 KEYNOTE-775 / Study 309 trial, which regimen should be recommended, and what is its signature class-effect toxicity requiring proactive clinical pharmacist management?
A 44-year-old woman is diagnosed with persistent, recurrent cervical squamous cell carcinoma with multiple metastatic pulmonary and retroperitoneal lesions. Immunohistochemical staining demonstrates a PD-L1 Combined Positive Score (CPS) of 15. The clinical oncology team plans to initiate first-line combination systemic therapy with cisplatin, paclitaxel, pembrolizumab, and bevacizumab based on the KEYNOTE-826 trial. During pre-treatment evaluation, which of the following clinical findings represents a critical contraindication or high-risk warning for the inclusion of bevacizumab in this regimen?